氯吡格雷联合脑苷肌肽治疗进展型脑梗死临床研究(附52例报告)  

Clincial study on the therapeutic effcts of Clopidogre and GM1 on progessive cerebral infarction

作　　者：胡新国[1] 金梅[1] 林军华[1] 金辉[1] 曹春华[1] 黄红雨[1] 李起栋[1] 

机构地区：[1]解放军171医院,江西九江332000

出　　处：《九江医学》2006年第1期54-56,共3页Jiujiang Medical Journal

摘　　要：目的:评价氯吡格雷联合脑苷肌肽治疗进展型脑梗死疗效。方法:将104例进展型脑梗死病人随机分成2组,应用氯吡格雷、脑苷肌肽组(52例)为治疗组,未用氯吡格雷、脑苷肌肽组(52)例为对照组;治疗组除应用氯吡格雷、脑苷肌肽外,两组治疗基本相同;观察两组治疗前、治疗48h、治疗2周的临床神经功能缺损程度评分标准(NDS)和治疗4周后临床疗效评定标准,进行评分比较。结果:治疗前两组NDS评分比较无统计学差异,治疗48h、治疗2周有统计学差异,治疗4周后临床疗效有统计学差异。结论:氯吡格雷联合脑苷肌肽注射液早期应用治疗进展型脑梗死,可明显改善临床症状,降低死亡率和致残率。OBJECTIVE:To evaluate the therapeutic effects of Clopidogre and GM1 on progessive cerebral infarction.METHOD:104 cases with progessive cerebral infarction were divided into two groups randomly,the patients received Clopidogre and GM1(52 cases) are therapeutic group,the others are control group.Except for routine treatment,the former received Clopidogre 300mg st,75mg qd and NS250ml+GM1 10ml ivgtt qd×14days.The latter received routine treatment.We observed and compared NDS/ Clinical effects in different time.RESULTS:The two groups had no statistics different in NDS before treament,but they had obvious statistics difference after 48h、two and four weeks.There is obvious statistics difference between before and after treament in therapeutic group.CONCLUSION:Clopidogre and GM1 can improve clinical symptoms,reduce the rate of death and handicap.

关 键 词：氯吡格雷 脑苷肌肽 进展型脑梗死 

分 类 号：R742[医药卫生—神经病学与精神病学]